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Summary
Background cdT cells play a crucial immunoregulatory role in the lung, maintaining nor-
mal airway tone and preventing hyperresponsiveness to innocuous allergen. During acute
inflammatory episodes, cdT cells promote resolution of acute inflammation. However,
their contribution to inflammation-associated airway remodelling remains unexplored.
Here we investigate the effects of cdT cell blockade on established allergic airway inflam-
mation and development of remodelling.
Methods Sensitised mice were exposed to prolonged ovalbumin challenge or continuous
house-dust mite exposure to induce chronic inflammation and remodelling. Functional
blocking anti-TCRd antibody was administered therapeutically, and parameters of airway
inflammation and remodelling were examined.
Results Therapeutic blockade of cdT cells prevented the typical resolution of acute airway
inflammation characterised by elevated eosinophil and Th2 cell numbers. Moreover, the
lung displayed exacerbated airway remodelling, typified by excess peribronchiolar colla-
gen deposition.
Conclusions These results demonstrate a unique role for cdT cells in constraining aller-
gen-induced airway remodelling. Manipulating the cdT cell compartment may therefore
contribute to strategies to prevent and treat remodelling.
Keywords airway remodelling, allergic inflammation, Th2 cells, cdT cells
Submitted 26 September 2013; revised 25 June 2014; accepted 10 July 2014
Introduction
In recent decades, allergic asthma has emerged as a
major global health burden. It is a chronic inflammatory
disease of the airways that results from environmental
interactions, complex immunobiology and genetic fac-
tors. Airway hyperreactivity (AHR), inflammation and
self-amplifying mediator release define the principal
pathological features of the disease [1–3]. Allergen chal-
lenge leads to an influx of large quantities of inflamma-
tory eosinophils to the conducting airways. Products of
these cells (enzymes, profibrotic mediators including
transforming growth factor-b) contribute to collateral
lung tissue damage [4, 5]. Persistent and unresolving air-
way inflammation cumulates in a variety of alterations
to airway architecture. Indeed, extensive injury to the
airway epithelium and activation of epithelial cells and
underlying fibroblasts are commonly described in
patients with asthma [1, 3, 6]. The resulting pathophysio-
logical changes to airway architecture, referred to as
‘remodelling’, encompass confounding subepithelial
fibrosis through deposition of collagen and dysregulated
matrix turnover [7]. This poorly understood process leads
to a progressive decline in lung function which correlates
with disease severity and poor response to therapy [8].
Appropriate regulation of inflammatory infiltrates repre-
sents a key strategy to limit allergic immunopathology
associated with the effector lymphocyte responses.
cdT cells constitute the major T cell component of
lung epithelium in the steady state [9, 10]. Although cdT
cells exhibit some characteristics of adaptive immunity,
they lack the antigen specificity of classical abT cells
[11], instead their functions are predominantly stress
surveillance in response to signals from their surround-
ing microenvironment and such stress signals are a sub-
stantial driver of immune responses [12]. In contrast,
regulatory functions of cdT cells have been demon-
strated during established disease to promote wound
healing [13, 14]. Interestingly, cdT cells are elevated in
the airways of asthmatics [15], and a regulatory cdT
cells population elicited in response to allergen exposure
has been observed in both mice and rats [16, 17]. We
recently demonstrated the vital contribution of
IL-17+cdT cells to resolution of acute allergic airway
inflammation [18]. However, the impact of these cells
on the development of remodelling has not yet been
investigated. We hypothesised that by providing a requi-
site inflammatory resolution mechanism in the airway,
cdT cells indirectly confound the remodelling processes
that are caused, in part, through repeated cycles of dam-
age and repair. We have used models of prolonged aller-
gen challenge to induce chronic inflammation-driven
remodelling and evaluated the role of cdT cells in this
process. Asthmatic patients present with established dis-
ease; therefore, understanding regulatory factors influ-
encing the course and outcome of chronic disease is
important. In contrast to previous studies employing
prophylactic measures to investigate cdT cells, a thera-
peutic approach was undertaken following induction of
established allergic airway disease. We determined that
depletion of cdT cells exacerbated remodelling as a con-
sequence of impaired inflammatory resolution.
Methods
Animals
Female BALB/c mice, purchased from Harlan Olac Ltd
(Bicester, UK), were housed at Imperial College animal
facility with food and water supplied ad libitum. UK
Home Office guidelines for animal welfare based on the
Animals (Scientific Procedures) act 1986 were observed.
In vivo experimental protocol
Sensitisation and airway challenge BALB/c mice were
sensitised intraperitoneally (i.p.) using 0.01 mg/mouse
OVA (Sigma, Poole, UK) in 0.2 mL Alum (Alu-Gal-Ser,
Serva Electrophoresis) on d0 and d12. Control mice
were sham sensitised using an equivalent volume of
PBS/Alum. Acute (day 24) and chronic (day 35 and 55)
airway disease was induced in using an established pro-
tocol of extended airway challenge [3]. Mice also
received 25 lg HDM extract (Dermatophagoides pter-
onyssinus in PBS) (Greer laboratories, Lenoir, North
Carolina, USA) or 25 lL PBS intranasally 5 days a week
for 5 weeks. Disease parameters were assessed in ani-
mals sacrificed by exsanguination under terminal
anaesthesia (100 mg/kg ketamine (Fort Dodge Animal
Health) and 10 mg/kg domitor (Pfizer) 24 h after final
allergen challenge.
Administration of function blocking anti-TCRd mAb
100 lL anti-TCR-d (200 lg/mL), hamster monoclonal
antibody against the cdTCR (a gift from L. Lefrancois)
was injected into the tail vein twice weekly from either
day 24 (protocol A) or 40 (protocol B) onwards in the
OVA model and from week 3 onwards in the HDM
model. Thorough blockade was ensured at each end-
point by flow cytometric analysis with anti-cdT cell
antibody from a different clone. Sham treatment was
accomplished with an equivalent volume of hamster Ig
(Jackson Laboratories).
Measurement of AHR
AHR was determined by direct measurements of resis-
tance and compliance in anesthetised and tracheosto-
mised mice in response to inhaled methacholine (MCh;
Sigma, Cambridge, UK) at concentrations of 3–100 mg/
mL for 1 min in an EMMS system (EMMS, Hampshire,
UK) in a modified version of previously described meth-
ods [19, 20].
Cell recovery
Airway Lumen Bronchoalveolar lavage (BAL) was per-
formed by three flushings of the lung with 0.4 mL PBS
via a tracheal cannula resulting in the recovery of 1 mL
BAL fluid. Lung parenchyma one lobe of lung tissue
was digested in complete media (RPMI + 10% FCS,
2 mM L-Glutamine, 100 U/mL Penicillin/Streptomycin)
containing 0.15 mg/mL collagenase (Type D, Roche
Diagnostics) and 25 lg/mL DNase (Type 1, Roche Diag-
nostics). Cells were recovered by filtration through a
70-lm nylon sieve (Falcon) and resuspended in 1-mL
complete media.
Quantification of eosinophils
Cells from the BALF and lung were counted and pelleted
onto glass slides by cytocentrifugation (5 9 104 cells/
slide). Differential cell counts were performed on
Wright-Giemsa-stained (Thermo) cytospins. Percentages
of eosinophils, lymphocyte/mononuclear cells, neu-
trophils and macrophages were determined by counting
their number (~400 total cells counted per slide) and
dividing this number by the total number of cells
counted. To obtain absolute numbers of eosinophils, the
percentage was multiplied by the total number of cells
obtained in the lavage fluid and lung homogenate.
Lung tissue histopathology
Four-lm paraffin-embedded lung sections were stained
with haematoxylin and eosin for evaluation of eosino-
philic infiltrates.
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Assessment airway remodelling
Peribronchiolar collagen deposition was quantified on
Sirius Red-stained sections viewed under polarised light
using Scion-Image software (Scion Corporation) [21].
The mean density of collagen staining was calculated
(pixels/lm2). Digital photographs representative of
bronchioles from each group were taken. Paraffin sec-
tions were stained with rabbit anti-mouse proliferating
cell nuclear antigen (PCNA) (Abcam, Cambridge, UK)
and a-smooth muscle actin (a-SMA) (Abcam) using an
avidin/biotin staining. Epithelial cell proliferation was
expressed as the % PCNA+ cells among total bronchio-
lar epithelial cells counted. The thickness of the
a-SMA+ peribronchiolar smooth muscle layer was
calculated by multiple measurements perpendicular to
the basement membrane.
Total lung collagen assay
Total collagen was assessed in lung homogenate using
a Sircoll dye kit (Biocolor Ltd) according to the manu-
facturer’s protocol.
Flow cytometric analysis
BAL and lung tissue leukocyte suspensions were stained
with anti-mouse CD3, anti-mouse CD4, anti-mouse-
TCRd, anti-mouse Vc4, anti-mouse IL-17A (BD Pharm-
ingen, Oxford, UK), anti-mouse T1/ST2 (Morwell
Diagnostics, Zurich, Switzerland), a-GalCer (Axxora
Biochemicals, Farmingdale, NY, USA) loaded CD1d
tetramers (ProImmune Ltd., Oxford, UK) or relevant
isotype controls. Flow cytometric analysis was per-
formed using a FACSCalibarTM (Becton Dickenson,
Oxford, UK) using CellQuest software.
Lung mediator analysis
One lobe of the lung was homogenised at 50 mg/mL in
Hanks buffered salt solution (HBSS) containing protease
inhibitor cocktail. Samples were centrifuged at 570 g
and cytokines measured in the supernatant (S1) fraction.
Cytokines are reported in mg/mL of the S1 fraction.
Paired antibodies for murine IL-4, IL-5 (BD Pharmingen)
and eotaxin-1/CCL11 (R&D Systems) were used in stan-
dardised sandwich ELISAs according to the manufac-
turer’s protocol. Lavage IL-13 was measured using a kit
according to manufacturer’s instructions (R&D Systems).
SEAP TGF-b Bioassay [22]
F11 cells (A gift from T. Wyss-Coray) seeded at
4.10 9 104 cells/well in 96-well flat-bottom tissue cul-
ture plates were incubated with 50 lL activated homog-
enised lung sample (activated by addition of 2.5 lL 6 M
HCl for 10 min followed by neutralisation to pH 7.4
with 6 M NaOH) for 24 h. Relative luminescence for
SEAP activity was measured using Great EscAPe SEAP
Reporter system 3 (Clontech, WI, USA) according to the
manufacturer’s instructions.
Data analysis
Data are expressed as mean  SEM unless otherwise
stated. Statistical significance between groups was
tested using a Mann–Whitney U-test. P of < 0.05 was
considered significant. Graph generation and statistical
analysis were performed using prism software (version
4.00; GraphPad).
Results
Prolonged airway challenge elicits increased pulmonary
cdT cells
Allergen provocation of OVA-sensitised mice elicits air-
way inflammation while prolonged aerosol challenge
with OVA is associated with a switch to a chronic
inflammatory remodelled phenotype [3]. To investigate
the role of cdT cells to the chronic remodelled pheno-
type in vivo, we assessed the effect of prolonged OVA
challenge (depicted schematically, Fig. 1a), on pulmo-
nary leukocytes within the airway lumen and tissue
compartments of OVA-sensitised mice by flow cytome-
try (Fig. 1b). Both total and Vc4+ cdT cells (which have
been shown to be regulatory in the asthmatic lung [23])
were significantly elevated following acute (day 24) and
extended challenge (day 35 and 55) in both the bron-
chiolar lavage (BAL) (Fig. 1b) and lung tissue (Fig. 1c).
Local changes in pulmonary cdT cell numbers were not
reflected in lung-draining lymph nodes, peripheral
lymph nodes or spleen (data not shown). There was an
increase in both IL-17+ T cells (Th17) and IL-17+ cdT
cells in response to OVA challenge (Fig. 1d,e). The
innate lymphocytes iNKT cells also increase following
OVA exposure (Fig. 1f,g). Th2 cells were also recruited
to the lung as part of the adaptive immune response to
allergen challenge (Fig. 1h,i). Peak recruitment of Th2
cells (Fig. 1i) and eosinophils [3] to the lung occurs on
d24 and decreases over time. Interestingly, the kinetics
of cdT cells during the course of allergen challenge did
not reflect this and remain elevated.
cdT cells regulate airway remodelling
To determine the contribution of cdT cells to airway
remodelling, anti-TCRd functional blocking antibody
GL3 was administered therapeutically after establish-
ment of allergic inflammation (Protocol A, Fig. 2a).
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Fig. 1. Pulmonary cdT cells are elevated following allergen exposure. Schematic OVA challenge model (a). Animals were systemically sensitised
with alum/OVA (alum/PBS) followed by acute OVA challenge (days 18–24). To induce chronic inflammation and remodelling, OVA challenges
were continued 39 weekly. Mice were sacrificed 24 h after final aerosol challenge on days 24, 35 and 55. Total and Vc4+ cdT cells in the BAL (b)
and lung (c). Th17 and IL-17+ cdT cells in the BAL (d) and lung (e). iNKT cells in the BAL (f) and lung (g). Th2 cells in the BAL (h) and lung (i).
Data represent mean  SEM (n = 6–12). *P < 0.05 compared to alum controls, (Mann–Whitney U-test). Alum controls from days 24, 35 and 55
were not significantly different between time points and were pooled for clarity.
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PCNA is an antigen expressed in the nuclei of
proliferating cells in S-phase of the cell cycle. OVA
challenge increased bronchiolar epithelial cell turnover/
proliferation as evidenced by increased numbers of
PCNA+ epithelial cells. Blockade of cdT cells delayed
the epithelial repair response induced in response to
(c)
(d)
(e)
(f)
(h) (i)
(a)
(g)
(b)
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allergen challenge (Fig. 2b). OVA induces phenotypic
changes of airway epithelial cells to a mucous secreting
phenotype [3]; however, blockade of cdT cells did not
affect mucous secretion (Fig. 2c). Increased deposition of
collagen around the airways was evident in Sirius Red-
stained lung sections of OVA-exposed mice (Fig. 2d).
Quantification of peribronchiolar collagen revealed anti-
TCRd antibody-treated mice had significantly more colla-
gen fibrils around the airways by day 55 (Fig. 2e). This
was also confirmed by analysis of total lung collagen
(Fig. 2f). Although excessive extracellular matrix deposi-
tion was observed in mice treated with anti-cdTCR anti-
body the lack of functional cdT cells did not influence
peribronchiolar airway smooth muscle mass (Fig. 2g).
Blocking cdT cells also did not affect airway hyperreac-
tivity (Fig. 2h) which is a function of airway smooth
muscle. TGF-b is profibrotic mediator vital to develop-
ment of airway remodelling in this model [3]. Substan-
tially more functionally active lung TGF-b was detected
on both days 35 and 55 in treated mice using a highly
sensitive bioassay (Fig. 2i) [22]. No differences in levels
of immunoregulatory IL-10 in the lung were observed
between groups (data not shown).
cdT cells regulate resolution of airway inflammation in
chronic eosinophilic airway inflammation
Prolonged OVA challenge is associated with a switch to a
chronic inflammatory phenotype which promotes devel-
opment of remodelling [3]. To investigate the participa-
tion of cdT cells in this process, we monitored pulmonary
eosinophilia following administration of the cdT cell
blocking antibody during established disease. Inflamma-
tory infiltrates were evaluated from lung histopathology
on days 35 and 55 following OVA challenge (Fig. 3a).
Immunopathological H&E scoring revealed a degree of
inflammatory resolve in OVA control mice between days
35 and 55, in accordance with published reports [3].
However, anti-cdTCR-treated mice did not exhibit a simi-
lar reduction (Fig. 3b). Quantification of cellular infil-
trates in the lung compartments demonstrated that anti-
cdT cell treatment resulted in exacerbated BAL (Fig. 3c)
and lung tissue eosinophilia (Fig. 3d) on day 55 when
compared to sham-treated OVA counterparts.
cdT cells regulate the CD4+Th2 responses during the
chronic disease stage
Differentiated Th2 cells, the driving force behind aller-
gic-type pathology in this system, were assessed on day
35 and day 55. Significant numbers of Th2 cells were
detected in OVA control mice on day 35; however, the
magnitude of this response had reduced by day 55
(Fig. 3e). In contrast, the lungs of anti-cdT cell anti-
body-treated OVA animals had substantially more lumi-
nal and lung tissue Th2 lymphocytes at both time
points. Th2-associated mediators indicate the magnitude
of the ensuing inflammatory response in the airways.
Lung Th2 cytokine and chemokine levels were equiva-
lent between groups on day 35. By day 55, mice receiv-
ing cdT cell blocking antibody had significantly
elevated Th2 cytokines IL-4 and IL-5 (Fig. 3f,g). IL-13
levels in the lung were not modulated by neutralisation
of cdT cells (Fig. 3h), although in the BALF, IL-13 lev-
els were significantly elevated (Fig. 3i). Eotaxin-1/
CCL11 levels were also augmented compared to Ig
control mice in the absence of cdT cells (Fig. 3j). In
contrast, there was no numerical difference in
CD4+CD25+FoxP3+Tregs or the Th1-associated cytokine
IFN-c detected between groups at any time point (data
not shown). Despite the increased pulmonary Th2
cytokines in the anti-cd antibody-treated mice, admin-
istration of the blocking antibody had no impact on
systemic IgE concentrations (Fig. 3k).
Depletion of cdT cells during the chronic phase affects
disease outcome
Because therapeutic blockade of cdT cells during acute
airway inflammation led to exacerbated levels of
inflammatory cells and mediators, it is difficult to iden-
tify the direct contribution of cdT cells to airway
remodelling. To this end, the role of cdT cells during
established remodelling was also assessed by delivering
anti-TCRd blocking antibodies from day 40 onwards,
when remodelling changes have become established
(Protocol B, Fig. 4a). Disease parameters were assessed
on day 55. Significantly elevated eosinophilia (Fig. 4b)
and Th2 cells (Fig. 4c) were observed in the airways of
Fig. 2. Blocking cdT cells during established inflammation promotes collagen deposition and TGF-b-mediated tissue remodelling in the allergic
lung. Protocol A – Following sensitisation (OVA/alum i.p.) and acute aerosolised OVA challenge (day 24), female BALB/c mice were administered
100 lL of 200 lg/mL anti-TCRd blocking mAb (or hamster Ig control) i.v. (twice weekly) and disease parameters assessed on days 35 and 55,
24 h after allergen challenge (a). % PCNA+ve epithelial cells (b). Mucous in the lung was measured by ELISA (c). Sirius Red-stained lung sections
demonstrating peribronchiolar collagen deposition from Alum and OVA-treated mice treated with either anti-cdTCR or the Ig control antibody (d),
original magnification 409. Quantitative analysis of subepithelial peribronchiolar collagen density determined from Sirius Red-stained collagen in
lung sections (e). Biochemical Sircol Assay of total lung collagen content (f). Peribronchiolar smooth muscle thickness (g). Airway resistance in
response to 30 mg/mL methacholine challenge (h). Detection of biologically TGF-b activity was measured in lung tissue homogenate using a
SEAP reporter bioassay (i). Data are expressed as mean  SEM, n = 8–12 per group. *P < 0.05 in comparison with OVA Ig controls (Mann–Whit-
ney U-test). Alum controls from days 35 and 55 were not significantly different between time points and are pooled for clarity.
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Fig. 3. Blockade of cdT cells during established inflammation promotes eosinophilic lung infiltration and elevated pulmonary Th2 responses. Peri-
bronchiolar infiltrates were examined on histological lung sections stained with H&E. Representative photomicrographs at 409 magnification (a).
Histopathological scoring of peribronchiolar submucosal lung inflammation (b). Eosinophils were quantified by differential counting of Wright-
Giemsa-stained BAL (c) and lung (d) cytospins. Th2 cells, defined as CD3+CD4+T1/ST2+, were evaluated by flow cytometric staining from lung leu-
kocyte preparations (e). Lung IL-4 (f), IL-5 (g) and IL-13 (h), BAL IL-13 (i), lung eotaxin/CCL11 (j) and serum OVA-specific IgE (k) levels assessed
by ELISA. Data are mean  SEM, n = 8–12 mice per group. *P < 0.05 in comparison with OVA Ig controls (Mann–Whitney U-test). Alum controls
from days 35 and 55 were not significantly different between time points and are pooled for clarity.
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mice treated with this protocol. No significant differ-
ence in subepithelial collagen deposition could be
detected (Fig. 4d). Total lung collagen content was
however significantly amplified in OVA-exposed mice
treated with the blocking antibody in comparison with
those receiving the control Ig (Fig. 4e). The increase in
pulmonary collagen was positively correlated with
elevated levels of TGF-b in the lung (Fig. 4f).
Therapeutic depletion of cdT cells in HDM-induced
allergic airway disease.
The OVA/alum model of allergic airway disease reca-
pitulates many of the clinical features of human asthma
and as such is a useful murine model to dissect the cel-
lular pathways involved in disease inception and propa-
gation. However, OVA is not a clinically relevant
allergen and the model relies upon peripheral sensitisat-
ion in the peritoneal cavity with the adjuvant alum
which skews the immune towards a Th2 response. We
therefore also investigated the role of pulmonary cdT
cells in a model of house-dust mite (HDM)-induced
allergic airway disease where sensitisation occurs
locally in the lung. Continuous exposure to HDM results
in recruitment of Th2 cells and cdT cells (Fig. 5a,b).
IL-17 levels in the lung were increased fivefold in
response to chronic HDM exposure (281  116 vs.
1450  126 pg/mL). The effect of therapeutic blockade
of cόT cells on HDM-induced allergic airway (Fig. 5c)
disease mirrored that previously observed in the OVA
model. The number of pulmonary eosinophils was
increased in response to allergen challenge with HDM,
and eosinophilia was augmented in the absence of
functional cόT cells (Fig. 5d). IL-4 and IL-5 were also
increased in the lung of HDM-exposed mice treated
with blocking antibody compared to those injected with
the Ig control antibody (Fig. 5e,f). However, blockade
of cdT cells did not influence pulmonary IL-13 levels in
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Fig. 4. Blocking cdT cells promotes established tissue remodelling in the allergic lung. Protocol B – 100 lL of 200 lg/mL anti-TCRd mAb (or
hamster Ig control) was administered i.v. (twice weekly) to female BALB/c mice after establishment of airway remodelling (day 43) and disease
parameters assessed on day 55, 24 h after final allergen challenge (a). Lung tissue eosinophils from each group were quantified by differential
counting of Wright-Gimsa-stained cytospins (b). Th2 cells, defined as CD3+CD4+T1/ST2+, were evaluated by flow cytometric staining (c). Quantita-
tive analysis of Sirius Red-stained lung sections for subepithelial peribronchiolar collagen density (d). Biochemical Sircol Assay of total lung col-
lagen content (e). Detection of biologically TGF-b activity was measured in lung tissue homogenate using a SEAP reporter bioassay (f). Data are
expressed as mean  SEM. n = 8–12 mice per group. *P < 0.05 in comparison with OVA controls (Mann–Whitney U-test). Alum controls from
days 35 and 55 were not significantly different between time points and are pooled for clarity.
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(a) (b)
(c)
(d)
(g)
(e) (f)
(h) (i)
(j)
(k) (l)
Fig. 5. Blockade of cdT cells during HDM-induced allergic airway disease promotes eosinophilic lung infiltration and airway remodelling. TH2
and cdT cells are increased in the BALF (a) and lung (b) following continuous challenge with 25 lg HDM. Following establishment of allergic air-
way disease, female BALB/c mice were administered 100 lL of 200 lg/mL anti-TCRd blocking mAb (or hamster Ig control) i.v. (twice weekly) and
disease parameters assessed at the end of week 5 (c). Lung tissue eosinophils from each group were quantified by differential counting of Wright-
Gimsa-stained cytospins (d). Lung IL-4 (e), IL-5 (f), IL-13 (g) and serum total IgE (h) were measured by ELISA. Airway resistance in response to
30 mg/mL methacholine challenge (i). Detection of biologically active TGF-b activity was measured in lung tissue homogenate using a SEAP
reporter bioassay (j). Quantitative analysis of Sirius Red-stained lung sections for subepithelial peribronchiolar collagen density (k). Peribronchiolar
smooth muscle thickness (l). Values are expressed as mean  SEM, n = 8–12 mice per group. *P < 0.05 in comparison with PBS controls,
†P < 0.05 in comparison with HDM Ig controls (Mann–Whitney U-test).
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the HDM model at the time point measured (Fig. 5g).
As observed in the OVA model, anti-cόTCR antibody
treatment did not impact immunoglobulin class switch-
ing to IgE secretion (Fig. 5h). Airway hyperreactivity
was also not affected by neutralisation of cdT cells
(Fig. 5i). Blockade of cdT cells further increased HDM-
induced TGF-b levels (Fig. 5j) which was associated
with an increase in peribronchiolar peribronchial colla-
gen deposition (Fig. 5k), as previously observed in the
OVA model. Airway smooth muscle mass was elevated
in the HDM-exposed mice treated with anti-cόTCR anti-
body compared to control Ig; however, this was not
statistically significant (Fig. 5l).
Discussion
cdT cells are key regulators of pulmonary homeostasis
and as such may influence the course and outcome of
allergic airway disease [15, 18]. In the present study, we
demonstrate that OVA-sensitised animals and mice con-
tinuously exposed to HDM for a prolonged allergen
challenge regimen exhibit local expansion of cdT cells
in the airways that remains elevated throughout the
chronic model. Functional blockade of cdT cells fol-
lowed by long-term allergen challenge exacerbated air-
way remodelling with particular reference to ECM
deposition. This was accompanied by excessive eosino-
philic, Th2 cellular infiltrates and a striking increase in
the activity of the profibrotic cytokine, TGF-b in the
lungs. Modulation of Tregs and Th1 responses did not
play a role in the disease phenotype of anti-TCRd-trea-
ted mice. Prolonged intermittent OVA challenge of sen-
sitised mice results in continual activation of repair
responses which are, in part, responsible for the remod-
elled lung [3, 7]. Our results show that cdT cells play an
important role in regulating established allergic airway
inflammation which impacts on development of aller-
gen-driven remodelling.
Chronic asthma is associated with inflammation and
structural remodelling of the airways. Infiltrating
inflammatory cells such as lymphocytes and eosinophils
secrete mediators which promote the development of
remodelling [24]. IL-5 is a recruitment and survival fac-
tor for eosinophils, and blocking IL-5 ameliorates colla-
gen deposition in mice and man indicating a role in
airway remodelling [25, 26]. In particular, eosinophils
are a source of TGF-b, an important profibrotic cyto-
kine associated with allergic pathology [27–29]. TGF-b
directly activates structural cells which drive remodel-
ling, and can induce production of other profibrotic
mediators (e.g. PDGF, VEGF). Both eosinophils and
TGF-b were elevated following blockade of cdT cells. In
the light of this information, impaired resolution of
inflammation is likely to be functionally responsible for
the exacerbation of airway remodelling.
In the absence of functional cdT cells, enhanced Th2
responses were evident. It has previously been shown that
modulation of cdT cells activates abT cells resulting in
marked T cell proliferation. The ligands involved in the
cross-talk between cd- and abT cells remain undefined,
but the data imply that antigen-specific T cells present in
the lung following OVA challenge (prior to administra-
tion of the functional blocking antibody) proliferate fur-
ther in the absence of cdT cells which act to constrain T
cells of the adaptive immune system and consequently
limit production of Th2 cytokines [30]. The increase in
IL-13 was restricted to the BALF compartment only.
Blockade of cdT cells did not augment IL-13 levels in the
lung which correlates with lung function and mucous
production which were not modulated in the anti-όTCR-
treated mice. Vc4+ dT cells are the largest resident popu-
lation of cdT cells in the adult lung and are induced fol-
lowing allergen challenge. Depletion of this subset of cdT
cells has also been associated with an increase in the
number of cytokine-producing T cells [31]. A potential
fibrotic role for the Th2 cytokines IL-4 and IL-13 has
been described [29, 32, 33]. IL-13 can induce TGF-b-
mediated fibrosis [33], while absence of IL-4 is associated
with a reduction of fibrosis in injury models [32].
Regulatory T cells are also involved in regulation of
allergic airway inflammation and development of remod-
elling [34]. cdT cells may influence pulmonary regulatory
T cell populations. This cannot be excluded as a contrib-
uting factor to the observed outcome of chronic-stage
disease in the current study. Using a second therapeutic
anti-TCRd administration protocol after remodelling had
been initiated (day 43, Protocol B), we also addressed
whether cdT cells could influence established airway
remodelling. In this situation, cdT cell blockade was also
associated with exacerbations of inflammatory and
remodelling parameters although these were less severe
and the concurrent profibrotic effect less pronounced.
This may likely be explained by the shorter duration of
cdT cell blockade (12 days vs. 31 days).
Regulation of adaptive immunopathology by cdT cells
has been demonstrated in a variety of acute inflammatory
disease settings [35]. Although several studies have
reported a requirement for cdT cells for full development
of an acute allergic phenotype [36, 37], these have used a
prophylactic approach to remove cdT cells. Using a clini-
cally relevant therapeutic approach, the present study
demonstrates a regulatory role for these cells during
established allergic disease induced experimentally by
systemic sensitisation to OVA and also in response to the
clinically relevant allergen HDM. The conflicting effects
of cdT cells during allergic asthma may be clarified by
the functional plasticity and diversity of cdT cells in
response to microenvironmental cues [12]. During infec-
tion, cdT cells display a biphasic stage-dependent
response. This corresponds to both promotion of patho-
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gen eradication through potentiating full development of
effector responses, followed by a later, immunoregulatory
response to restore homeostasis [35]. This dual function
displays little evidence of antigen specificity and as cdT
cells are intimately associated with tissues such as gut,
lung and skin where pathogen encounter is greatest and
heightened immune defence required is suggestive of a
general ‘innate-like’ defence mechanism. Fitting with
such a model, we have previously identified an IL-17-
secreting subpopulation of cdT cells to play a key role in
inflammatory resolution during OVA-induced allergic
disease in the lung [18]. In the present study, we have
shown cdΤ cells remain elevated during chronic HDM
challenge concomitant with an increase in pulmonary IL-
17 levels (data not shown). cdT cell blockade during pro-
longed allergen exposure resulted in exacerbated eosino-
philia and airway remodelling confirming a regulatory
role for these cells in constraining allergen-induced pul-
monary pathology. This study clearly illustrates the con-
sequences of impaired resolution on tissue remodelling of
the airways following continuous allergen challenge.
Overall, the current study strengthens the expanding par-
adigm of cdT cells as sentinels of epithelial tissues with a
key function in minimising persistent inflammation and
associated tissue damage observed in so many chronic
inflammatory diseases including asthma.
The pulmonary epithelium is the largest mucosal bar-
rier to the environment in the body and, in addition to
the underlying mesenchyme, is considered an active
player in the allergic response [38, 39]. cdT cells reside
within the epithelium and recognise antigens expressed
by stressed/damaged tissue cells. This is thought to
facilitate cdT cell-dependent maintenance of tissue
integrity [40]. In the skin, absence of resident cd T cells
results in a significant delay in wound healing and
impaired epidermal cell proliferation [13]. Intra-epithe-
lial cd T cells have also been shown to participate in
tissue repair in the gut [41]. We have extended these
observations and shown that in the lung, mice lacking
functional cdT cells exhibit a delay in epithelial regen-
eration in response to allergen challenge. Mice deficient
in cdT cells are also unable to resolve skin wounds, and
cdT cells can directly influence bleomycin-induced lung
fibrosis [14]. Their pro-resolving immunoregulatory
function is thought to be aided by a direct effect on
wound healing [9] further strengthening the paradigm
of cdT cells as effective regulators of tissue repair and
epithelial homeostasis [13]. Furthermore, cdT cell-
induced hyaluronan contributes to resolution of inflam-
matory responses constituting an active part of immu-
noregulation to prevent chronic disease [42]. Tissue
remodelling during chronic inflammatory diseases such
as asthma has been considered as a wound healing
response. One can speculate that lung remodelling may
occur due to ineffective resolution of acute inflamma-
tory episodes triggered by each exposure to allergen.
Despite evidence for a direct effect on wound healing,
the contribution of cdT cells to regulation of established
remodelling in this study cannot be uncoupled from
their regulatory influence during established disease as
inflammation, a contributor to remodelling, is also
exacerbated in the absence of cdT cells.
The data presented in the present study demonstrate
for the first time that cdT cells are upregulated during
chronic allergic airway disease induced both systemi-
cally and locally in the lung and have the profound
ability to affect the natural resolution of chronic
inflammation and influence the development of
remodelling. Furthermore, cdT cells are able to affect
responses even when allergic disease is established.
An important role for cdT cells in regulating inflam-
mation has previously been implied during acute
infectious inflammation. The information presented in
the present study strengthens the expanding paradigm
of cdT cells as regulators of inflammation-associated
tissue injury. The role of cdT cells in asthma patho-
genesis remains unclear. During symptomatic asthma
exacerbations, cdT cells are reportedly increased [43–
45]. However, there are also patient data indicating
that there is no change in cdT cells in asthmatic
cohorts compared with non-asthmatics [46, 47] and
that cdT cells are reduced in allergic asthma com-
pared with healthy controls [48]. It is tempting to
speculate based on the results of the present study
that in some subsets of patients with asthma, a failure
to upregulate cdT cells may result in an uncontrolled
eosinophilic and Th2-mediated immune response with
dysregulated ECM deposition and airway remodelling.
The increased understanding of factors regulating
chronic inflammation and its contribution to the path-
ophysiological features of allergic disease may open
up new avenues for future anti-inflammatory asthma
treatment strategies.
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